Renée S. Martin

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

Richard Furie, G. Léon, Meenu Thomas et al. · Annals of the Rheumatic Diseases · 2014 · 165 citations

Life Sciences, Immunology, Pharmacology +17

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Joan T. Merrill, William Shanahan, Morton Scheinberg et al. · Annals of the Rheumatic Diseases · 2018 · 155 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +12

AF‐353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist

Joel R. Gever, Rothschild Soto, Robert Henningsen et al. · British Journal of Pharmacology · 2010 · 130 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Selective 5HT2A and 5HT6 Receptor Antagonists Promote Sleep in Rats

Stephen R. Morairty, L. Hedley, Judith Flores et al. · SLEEP · 2008 · 116 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Emergency Department Length of Stay Is an Independent Predictor of Hospital Mortality in Trauma Activation Patients

Nathan T. Mowery, Stacy D. Dougherty, Amy N. Hildreth et al. · The Journal of Trauma: Injury, Infection, and Critical Care · 2011 · 115 citations

Medicine, Emergency Medicine, Surgery +11